Trial reportHERD2015
From Laboratory Research to a Clinical Trial: Copper Alloy Surfaces Kill Bacteria and Reduce Hospital-Acquired Infections.
Trial report in HERD, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Does copper treatment of commonly touched surfaces reduce healthcare-acquired infections? A systematic review and meta-analysis.The Journal of hospital infection · 2020Pooled it
- A Review of the Design and Synthesis of (Electro)chemically Induced Three-dimensional Nanoporous Copper: A Strategic Element for COACS omega · 2026Review
- Shikonin-copper coordination nanoparticles for enhanced antibacterial and antibiofilm activity against Staphylococcus aureus.Scientific reports · 2025Article
- Environmental hygiene strategies to combat antimicrobial resistance in healthcare settings.Antimicrobial stewardship & healthcare epidemiology : ASHE · 2025Review
- In vitro assessment of antibacterial and antiviral activity of three copper products after 200 rounds of simulated use.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2024Article
- A Long-Term Study on the Bactericidal Effect of ZrN-Cu Nanostructured Coatings Deposited by an Industrial Physical Vapor Deposition System.Nanomaterials (Basel, Switzerland) · 2024Article
- Article
- Reduction of bioburden on large area surfaces through use of a supplemental residual antimicrobial paint.PloS one · 2024Article
- Robust and Transparent Silver Oxide Coating Fabricated at Room Temperature KillsMicroorganisms · 2023Article
- Computer Simulation of the Interaction between SARS-CoV-2 Spike Protein and the Surface of Coinage Metals.Langmuir : the ACS journal of surfaces and colloids · 2022Article
- Copper-coated hospital surfaces: reduction of total bacterial loads and resistant Acinetobacter spp.AMB Express · 2022Article
- Antibacterial and Antiviral Effects of Ag, Cu and Zn Metals, Respective Nanoparticles and Filter Materials Thereof against Coronavirus SARS-CoV-2 and Influenza A Virus.Pharmaceutics · 2022Article
- Effect of Reducing Agent on Characteristics and Antibacterial Activity of Copper-Containing Particles in Textile Materials.Materials (Basel, Switzerland) · 2022Article
- Antibacterial Activity of Copper Particles Embedded in Knitted Fabrics.Materials (Basel, Switzerland) · 2022Article
- Experimental Evolution of Copper Resistance inAntibiotics (Basel, Switzerland) · 2022Article
- Residual antimicrobial coating efficacy against SARS-CoV-2.Journal of applied microbiology · 2022Article
- Recent Advances in Metal-Based Antimicrobial Coatings for High-Touch Surfaces.International journal of molecular sciences · 2022Review
- Antiviral properties of copper and its alloys to inactivate covid-19 virus: a review.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2021Review
- Quantitative Evaluation of Nucleic Acid Degradability of Copper Alloy Surfaces and Its Correlation to Antibacterial Activity.Antibiotics (Basel, Switzerland) · 2021Article
- Virus matrix interference on assessment of virucidal activity of high-touch surfaces designed to prevent hospital-acquired infections.Antimicrobial resistance and infection control · 2021Article
Corrections and comments
- Commented on by
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis is a translational science article that discusses copper alloys as antimicrobial environmental surfaces. Bacteria die when they come in contact with copper alloys in laboratory tests. Components made of copper alloys were also found to be efficacious in a clinical trial.
backgroundThere are indications that bacteria found on frequently touched environmental surfaces play a role in infection transmission.
methodsIn laboratory testing, copper alloy samples were inoculated with bacteria. In clinical trials, the amount of live bacteria on the surfaces of hospital components made of copper alloys, as well as those made from standard materials, was measured. Finally, infection rates were tracked in the hospital rooms with the copper components and compared to those found in the rooms containing the standard components.
resultsGreater than a 99.9% reduction in live bacteria was realized in laboratory tests. In the clinical trials, an 83% reduction in bacteria was seen on the copper alloy components, when compared to the surfaces made from standard materials in the control rooms. Finally, the infection rates were found to be reduced by 58% in patient rooms with components made of copper, when compared to patients' rooms with components made of standard materials.
conclusionsBacteria die on copper alloy surfaces in both the laboratory and the hospital rooms. Infection rates were lowered in those hospital rooms containing copper components. Thus, based on the presented information, the placement of copper alloy components, in the built environment, may have the potential to reduce not only hospital-acquired infections but also patient treatment costs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.